Table 1.
Clinical characteristics of subjects, HTN history and treatment, and home BP measurements (three measurements morning and evening, three consecutive days)
| Characteristics | HS (n=82) | Het (n=81) | GS (n=79) | ANOVA P Value |
|---|---|---|---|---|
| Whole population | ||||
| Age, yr | 40.3 [28.1; 56.1] | 43.2 [25.7; 58.4] | 39 [27.7; 51.1] | 0.85 |
| BMI, kg/m2 | 23.8 [21.5; 25.4] | 23.2 [21.6; 25.7] | 23.8 [20.7; 26.5] | 0.89 |
| Women/men (ratio) | 44/38 (0.53) | 46/35 (0.57) | 42/37 (0.53) | 0.9 |
| Past history of HTN | 0 | 6 | 6 | |
| Newly discovered HTN | 7 | 3 | 5 | |
| White-coat HTN | 3 | 8 | 2 | |
| Antihypertensive drugs | ||||
| Potassium-sparing diuretics | 0 | — | 30 | |
| ACE inhibitors | 0 | 3 | 1 | |
| ARB | 0 | 3 | 1 | |
| β-blockers | 0 | 4 | 4 | |
| Calcium channel blockers | 0 | 2 | — | |
| Home BP | ||||
| SBP, mm Hg | 118 [112; 127]a | 116 [108; 127] | 113 [107; 121] | 0.04 |
| Diastolic BP, mm Hg | 71 [66; 76] | 70 [64; 76] | 70 [66; 74] | 0.82 |
| HR, bpm | 70 [63; 77]b | 69 [64; 77]a | 74 [69; 79] | 0.005 |
| Subpopulations | (n=82) | (n=74) | (n=49) | |
| Antihypertensive drugs | 0 | 0 | 0 | |
| Home BP | ||||
| SBP, mm Hg | 118 [112; 127] | 116 [108; 125] | 113 [107; 124] | 0.13 |
| Diastolic BP, mm Hg | 71 [66; 76] | 69 [64; 76] | 69 [66; 72] | 0.59 |
| HR, bpm | 70 [63; 77]a | 69 [63; 79]a | 75 [69; 79] | 0.009 |
Whole population analyses: all participants were included in the study. Subpopulation: hypertensive or diabetic participants were excluded as were patients with GS treated with potassium-sparing diuretics. Data are presented as median [IQR]. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
For HS or Het versus patients with GS.
a
P<0.05.
b
P<0.001.